Pediatric Drugs

, Volume 16, Issue 3, pp 213–227

Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia

Review Article

DOI: 10.1007/s40272-014-0067-3

Cite this article as:
Faulk, K., Gore, L. & Cooper, T. Pediatr Drugs (2014) 16: 213. doi:10.1007/s40272-014-0067-3

Abstract

Although acute myelogenous leukemia (AML) accounts for <20 % of leukemia in children, it is responsible for over half of all pediatric leukemia deaths. Improvement in event-free survival rates, now over 50 %, are due largely to intensification of chemotherapy, aggressive supportive care, development of risk stratification based on cytogenetic and molecular markers, and improved salvage regimens. Despite this improvement over the past few decades, the survival rates have recently plateaued, and further improvement will need to take into account advances in molecular characterization of AML, development of novel agents, and better understanding of host factors influencing toxicity and response to chemotherapy. This article reviews the epidemiology and biology trends in diagnosis and treatment of pediatric acute myelogenous leukemia.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Colorado School of Medicine/Anschutz Medical CampusAuroraUSA
  2. 2.Children’s Hospital ColoradoAuroraUSA
  3. 3.University of Colorado Cancer CenterAuroraUSA
  4. 4.Developmental Therapeutics ProgramAuroraUSA
  5. 5.Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta/Emory UniversityAtlantaUSA